Compare Bristol-Myers Squibb Co (BMY) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Paycom Software Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.4 (market cap $116.30B), while Paycom Software Inc trades at $146.76 (market cap $6.70B). The key difference: Bristol-Myers Squibb Co is far larger — about 17.4× Paycom Software Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PAYC | |
|---|---|---|
Market Cap | $116.30B | $6.70B |
Sector | Health | Technology |
52-Week High | $62.37 | $238.80 |
52-Week Low | $42.60 | $113.59 |
Enterprise Value | $152.24B | $7.31B |
Dividend Yield | 4.42% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Paycom Software (PAYC) trades at $146.50, up 5.34% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 22.44% net income margin and 37.15% ROE, though Q2 2026 earnings are pending. Recent news highlights product innovation with the launch of Asset Management tool and board appointments, supporting growth prospects in the HCM software sector.
Outlook remains positive with analyst consensus price target of $151 suggesting modest upside, balanced by high valuation multiples and competitive pressures. Key risks include execution challenges in maintaining growth momentum and sensitivity to economic cycles affecting HR software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
